PF-06815345

Cat. No.:	HY-112598
CAS No.:	1900686-46-5
Molecular Formula:	$C_{27}H_{29}ClFN_9O_4$
Molecular Weight:	598.03
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PF-06815345 is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC_{50} value of 13.4 μM. PF-06815345 significantly decreases the PCSK9 level in vivo in mouse[1][2].
IC_{50} & Target	IC50: >20 μM (cell based), 13.4 (cell free) for Proprotein convertase subtilisin/kexin type 9 (PCSK9)[2]
In Vitro	PF-06815345 (Example 7) (1-30 μM; 5-1440 min) in human enterocyte and hepatocyte with CL_{int} values of <82.9 μL/min/mg and 97.6 μL/min/mg, respectively[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	PF-06815345 (Example 7) (100-500 mg/kg; p.o; single dose) lowers the level of PCSK9 in humanized PCSK9 mouse model. It lowers plasma PCSK9 to 72% at 500 mg/kg 4 hr later treatment[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Akin A, et al. Overcoming the Challenges of Making a Single Enantiomer N-1 Substituted Tetrazole Prodrug Using a Tin-Mediated Alkylation and Enzymatic Resolution[J]. Organic Process Research & Development, 2019, 23(6): 1167-1177.

[2]. Darout E, et al. Preparation of substituted amide compounds as PCSK9 inhibitors: Canada, CA2907071 A1 2016-04-08.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA